Clinical Trial Update: Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating preoperative lenvatinib plus pembrolizumab in early-stage triple-negative breast cancer is currently recruiting. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Triple Negative Breast Cancer | Phase 1 | Status: RECRUITING